Want to see JP:4570 full AI Analyst Report?

Immuno-Biological Laboratories Co., Ltd. (4570) Price & Analysis

0 Followers

4570 Stock Chart & Stats

¥1404.00

¥18.00(3.96%)

At close: Jan 08 4:00 PM EST

¥1404.00

¥18.00(3.96%)

Day’s Range― - ―

52-Week Range¥464.00 - ¥3,820.00

Previous CloseN/A

Volume75.00K

Average Volume (3M)23.51K

Market Cap

¥9.28B

Enterprise Value¥8.23K

Total Cash (Recent Filing)¥989.47M

Total Debt (Recent Filing)¥177.09M

Price to Earnings (P/E)25.2

Beta0.87

Next Earnings

Oct 30, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend Yield0.6%

Share Statistics

EPS (TTM)35.32

Shares Outstanding9,314,590

10 Day Avg. Volume28,690

30 Day Avg. Volume23,506

Financial Highlights & Ratios

PEG Ratio1.18

Price to Book (P/B)6.78

Price to Sales (P/S)12.44

P/FCF Ratio46.69

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Conservative Balance SheetVery low leverage and a strengthening equity base provide durable financial flexibility. With debt-to-equity near 0.10 the company can fund working capital or R&D without heavy refinancing, absorb demand swings, and preserve investment optionality across 2–6 months and beyond.

Strong Cash GenerationRebounded operating and free cash flow (FCF ~¥268M) that tracks ~89% of net income indicates the business can internally fund operations, modest capex and working capital. This sustained cash conversion supports self-funded growth and reduces reliance on external financing in the medium term.

Profitability Turnaround And Strong MarginsConsistently high gross and operating margins imply pricing power and efficient production for reagent products. The recent move to sustained profitability and ROE improvement signals the firm can generate durable returns on capital, supporting reinvestment and shareholder distributions over time.

Bears Say

Turnaround Durability RiskA meaningful recovery is evident, but prior deep losses through 2021–2023 show earnings volatility. That history raises the risk that margin and revenue gains may be cyclical or project-driven, making it uncertain whether current profitability persists over the next several quarters without continued demand stability.

Inconsistent Historical Cash FlowUneven cash flow history undermines planning and increases the chance of needing external funding during downturns. Despite strong 2026 FCF, prior negative cash flow years highlight operational sensitivity to demand and stock/receivables cycles that could re-emerge and pressure liquidity or strategic investments.

Narrow Product Mix And Limited ScaleHeavy reliance on consumable reagent sales and the absence of meaningful services, licensing or partnerships concentrate revenue risk. Combined with a small employee base (54), this limits diversification and scale economies, potentially capping growth and making the company more exposed to shifts in academic and R&D spending.

4570 FAQ

What was Immuno-Biological Laboratories Co., Ltd.’s price range in the past 12 months?

Immuno-Biological Laboratories Co., Ltd. lowest stock price was ¥464.00 and its highest was ¥3820.00 in the past 12 months.

What is Immuno-Biological Laboratories Co., Ltd.’s market cap?

Immuno-Biological Laboratories Co., Ltd.’s market cap is ¥9.28B.

When is Immuno-Biological Laboratories Co., Ltd.’s upcoming earnings report date?

Immuno-Biological Laboratories Co., Ltd.’s upcoming earnings report date is Oct 30, 2026 which is in 77 days.

How were Immuno-Biological Laboratories Co., Ltd.’s earnings last quarter?

Immuno-Biological Laboratories Co., Ltd. released its earnings results on Aug 07, 2026. The company reported ¥10.76 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.

Is Immuno-Biological Laboratories Co., Ltd. overvalued?

According to Wall Street analysts Immuno-Biological Laboratories Co., Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Immuno-Biological Laboratories Co., Ltd. pay dividends?

Immuno-Biological Laboratories Co., Ltd. pays a Notavailable dividend of ¥7.5 which represents an annual dividend yield of 0.6%. See more information on Immuno-Biological Laboratories Co., Ltd. dividends here

What is Immuno-Biological Laboratories Co., Ltd.’s EPS estimate?

Immuno-Biological Laboratories Co., Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Immuno-Biological Laboratories Co., Ltd. have?

Immuno-Biological Laboratories Co., Ltd. has 9,314,590 shares outstanding.

What happened to Immuno-Biological Laboratories Co., Ltd.’s price movement after its last earnings report?

Immuno-Biological Laboratories Co., Ltd. reported an EPS of ¥10.76 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.261%.

Which hedge fund is a major shareholder of Immuno-Biological Laboratories Co., Ltd.?

Currently, no hedge funds are holding shares in JP:4570

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Immuno-Biological Laboratories Co., Ltd.

Immuno-Biological Laboratories Co., Ltd. (IBL) is a global entity dedicated to the research, development, production, and distribution of immunological reagents. The company's diverse offerings include ELISA assay kits designed for the precise quantitative measurement of targeted substances, alongside comprehensive research support services focusing on areas such as Alzheimer's disease, metabolic syndrome, and cancer. IBL also caters to specific client needs through customized services for antibody production and the development of bespoke ELISA systems. A prominent service is LipoSEARCH, which provides tailored lipoprotein profiling and analysis utilizing gel-filtration high-performance liquid chromatography. This advanced method allows for the in-depth examination of even minute plasma or serum samples from both humans and small animals, supporting a broad spectrum of research, including lipid metabolism, the creation of pharmaceuticals for lifestyle-related diseases, functional food development, and clinical investigations. For animal health, IBL offers LipoTEST, a diagnostic and health screening tool for veterinary clinics, complemented by personalized biomarker testing services for lifestyle-related conditions. Furthermore, the company operates an innovative protein production division that leverages transgenic silkworms. This technology is instrumental in manufacturing antibodies for research and diagnostic applications, human collagen for cosmetic use, proteins for drug development, and other specialized proteins. Established in 1982, Immuno-Biological Laboratories Co., Ltd. is headquartered in Fujioka, Japan.